Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th
Clinical trial NCT07655115 · RECRUITING
Trial details
- NCT number
- NCT07655115
- Sponsor
- Hospital General Universitario Gregorio Marañon
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-20
- Primary completion
- 2026-12-31
- Enrollment
- 103
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.